


PHARMACEUTICAL 2018











PHARMACEUTICAL 2018



CymaBay Therapeutics Inc. Rank 70 of 342



The relative strengths and weaknesses of CymaBay Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CymaBay Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 116% points. The greatest weakness of CymaBay Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 19% points.

The company's Economic Capital Ratio, given in the ranking table, is 192%, being 146% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	103,544
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,310
Liabilities, Non-Current	0
Other Assets	634
Other Compr. Net Income	-43
Other Expenses	1,080
Other Liabilities	2,990
Other Net Income	4,848
Other Revenues	0
Property and Equipment	69
Research and Development	18,938
Selling, General and Administrative Expense	12,387

Output Variable	Value in 1000 USD
Assets	104,247
Liabilities	19,300
Expenses	32,405
Revenues	0
Stockholders Equity	84,947
Net Income	-27,557
Comprehensive Net Income	-27,578
Economic Capital Ratio	192%

